Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD1 | P21728 | 4/20 | 0.49 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | DRD2 | P14416 | 1/20 | 0.47 |
| ▸ | DRD4 | P21917 | 1/20 | 0.47 |
| ▸ | DRD5 | P21918 | 1/20 | 0.47 |
| ▸ | DRD3 | P35462 | 1/20 | 0.47 |
| ▸ | PDCD1 | Q15116 | 6/20 | 0.47 |
| ▸ | CD274 | Q9NZQ7 | 6/20 | 0.47 |
| ▸ | ELANE | P08246 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.40 |
| ▸ | NAT1 | P18440 | 1/20 | 0.40 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.39 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30498620 | 1.00 | DRD1 (0.49) | DRD1CYP2A6ALDH1A1DRD2DRD4 | |
| SCHEMBL29016808 | 0.87 | APP (0.40) | DRD1CYP2A6ALDH1A1DRD2DRD4 | |
| SCHEMBL35966 | 0.86 | ALDH1A1 (0.59) | DRD1CYP2A6ALDH1A1DRD2DRD4 | |
| SCHEMBL28602844 | 0.85 | DRD1 (0.42) | DRD1CYP2A6ALDH1A1DRD2DRD4 | |
| SCHEMBL30704990 | 0.85 | DRD1 (0.42) | DRD1CYP2A6ALDH1A1DRD2DRD4 | |
| SCHEMBL5964342 | 0.85 | CYP2A6 (0.45) | DRD1CYP2A6ALDH1A1DRD2DRD4 | |
| Hydrogen Sulfide SCHEMBL27896687 | 0.84 | ALDH1A1 (0.56) | DRD1CYP2A6ALDH1A1DRD2DRD4 | |
| SCHEMBL31620987 | 0.83 | PDCD1 (0.51) | PDCD1CD274 | |
| SCHEMBL20540439 | 0.82 | DRD1 (0.41) | DRD1CYP2A6ALDH1A1DRD2DRD4 | |
| SCHEMBL20540212 | 0.81 | DRD1 (0.42) | DRD1CYP2A6ALDH1A1DRD2DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230226062-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2023-07-20 | — | — | US | disclosed |
| US-20230226062-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2023-07-20 | — | — | US | disclosed |
| US-20230226062-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2023-07-20 | — | — | US | disclosed |
| WO-2018119263-A1 | HETEROCYCLIC COMPOUNDS DERIVATIVES AS PD-L1 INTERNALIZATION INDUCERS | INCYTE CORPORATION (US) | 2018-06-28 | — | — | WO | disclosed |
| US-20180177784-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2018-06-28 | — | — | US | disclosed |
| US-20180177784-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2018-06-28 | — | — | US | disclosed |
| US-20180177784-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2018-06-28 | — | — | US | disclosed |
| WO-2018119263-A1 | HETEROCYCLIC COMPOUNDS DERIVATIVES AS PD-L1 INTERNALIZATION INDUCERS | INCYTE CORPORATION (US) | 2018-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180177784-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | CD274, PDCD1, PDCD1LG2 | DRD1 2793/4885CYP2A6 2011/4885ALDH1A1 122/4885 |
| US-20230226062-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | CD274, PDCD1, PDCD1LG2 | DRD1 2793/4885CYP2A6 2011/4885ALDH1A1 122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.